FPT-SOFTWARE
5.8.2024 09:31:33 CEST | Business Wire | Press release
Global technology company FPT Software, a subsidiary of FPT Corporation, and KITZ Corporation, a world-leading manufacturer of industrial valves and fluid control products, recently signed a strategic partnership agreement. The collaboration leverages FPT Software’s scalable workforce and robust expertise to accelerate the digital transformation initiatives across KITZ’s manufacturing and business operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240804936324/en/
The signing ceremony took place in Tokyo, Japan, with KITZ Corporation CEO Makoto Kohno, FPT Corporation EVP and FPT Software CEO Pham Minh Tuan, and senior executives from both sides. (Photo: Business Wire)
Under the agreement, FPT Software will provide digital solutions to enhance KITZ’s product development and design, global supply chain, maintenance services, and sales and marketing activities. FPT Software will also enhance KITZ’s IT infrastructure through cutting-edge, AI-infused solutions to facilitate its operation and manufacturing with greater precision, efficiency, and safety.
“Driving agility, scalability, and enhanced productivity for our clients has always been FPT Software’s priority. With two decades of experience accompanying industry giants in Japan, a diversified delivery network, and a high-quality workforce globally, we are confident to help KITZ streamline operations and improve time-to-market to stay ahead of the rapidly changing manufacturing landscape,” said Pham Minh Tuan, FPT Corporation Executive Vice President and FPT Software Chief Executive Officer.
"I believe that forming a strategic partnership with FPT, a company that provides the latest technologies and services in the digital field, is a significant step forward. We are currently constructing a factory in Vinh Phuc Province, Vietnam, to manufacture and sell stainless steel valves, which are expected to be in high demand in the future, and a factory to produce high-purity gas valves for the semiconductor equipment market. In Vietnam, which is experiencing remarkable growth, we will continue to provide products and services tailored to our customers' markets and regions by partnering with FPT, a global company that has been at the forefront of DX initiatives for many companies,” said Makoto Kohno, KITZ Corporation Chief Executive Officer.
With nearly 20 years in Japan, FPT Software has become one of the largest foreign technology firms in terms of workforce, with 3,500 employees across 17 local offices and innovation hubs, as well as 15,000 global employees dedicated to the Japanese market. The company has provided services and solutions to over 450 clients worldwide, supporting their digital transformation through strategic consulting services and advanced technological solutions such as AI, machine learning, and cloud computing. The IT firm also plays a significant role in promoting technology cooperation and development between Vietnam and Japan, notably an active member of the Japan Business Federation (Keidanren) and the chair of the Vietnam Association of Digital Transformation in Japan (VADX Japan).
Manufacturing is among FPT Software's key domains. It provides comprehensive strategies and execution processes for digital factories on a global scale, leveraging its deep expertise and wide skills network to deliver complex end-to-end projects that enhance manufacturing operations. These proven competencies and success place FPT Software as a leader and disruptor in manufacturing services by IDC MarketScape and HFS Horizons.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240804936324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom